M.D. Sass maintains its Average Parent rating as the firm evolves its business.
The firm continues to de-emphasize private equity and focus on its in-house strategies. Founder and CEO Marty Sass has notched a 52-year career at his firm and now directs his energy to the private equity side of the business, but M.D. Sass expects to shut down these endeavors in 2025, at least for now. Meanwhile, the firm's next generation remains focused on the firm's compact lineup of strategies.
Since Sass ceded responsibilities for the public equities business to his son, Ari Sass, at the end of 2018, the younger Sass has nurtured a team culture of collaboration that is intent on being flexible yet process-oriented. As a result, the performance of the firm's single equity portfolio, Concentrated Value, while volatile, has landed firmly in its category's top decile since its 2019 inception. The fixed-income team has been led by industry veteran Lipkee Lu since 2019, and he is supported by four experienced fixed-income professionals. That team plays to its strengths, almost exclusively focusing on mortgages across products.
As the firm’s business has shifted, it hopes to grow by expanding access to its capabilities. The Concentrated Value strategy has grown considerably over the past year, and M.D. Sass plans to launch a UCITS version in Europe in 2025's first quarter. The firm is also considering exchange-traded funds and adjacencies to existing strategies.
Note: This share class' Parent Pillar rating is analyst-driven, as its Branding Name, MD Sass (Branding Name ID: BN00000DJY), is covered by Morningstar Manager Research.